Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

Abasaglar® (insulin glargine): Use in Hepatic Impairment

The effect of hepatic impairment on the pharmacokinetics of Abasaglar has not been studied.

Detailed Information

The effect of hepatic impairment on the PK of Abasaglar has not been studied.1

In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.2

As with all insulin products, more frequent glucose monitoring and dosage adjustment may be necessary for Abasaglar in patients with hepatic impairment. Patients with hepatic impairment may be at higher risk for hypoglycemia.1

Some studies with human insulin have shown increased circulating levels of insulin in patients with hepatic failure.1


1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.


Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

PK = pharmacokinetic

Date of Last Review: April 02, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request